Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Review

Insights into organoid-based modeling of COVID-19 pathology

Authors: Mohadese Hashem Boroojerdi, Tariq Al Jabry, Seyed Mohamad Javad Mirarefin, Halima Albalushi

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Since December 2019, various types of strategies have been applied due to the emergent need to investigate the biology and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to discover a functional treatment. Different disease modeling systems, such as mini-organ technology, have been used to improve our understanding of SARS-CoV-2 physiology and pathology. During the past 2 years, regenerative medicine research has shown the supportive role of organoid modeling in controlling coronavirus disease 2019 (COVID-19) through optimal drug and therapeutic approach improvement. Here, we overview some efforts that have been made to study SARS-CoV-2 by mimicking COVID-19 using stem cells. In addition, we summarize a perspective of drug development in COVID-19 treatment via organoid-based studies.
Literature
1.
Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020;395(10223):507–13.CrossRef
2.
3.
Guan W-J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.PubMedCrossRef
4.
5.
Yang L, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125–36.PubMedPubMedCentralCrossRef
6.
Basiri A, et al. Regenerative medicine in COVID-19 treatment: real opportunities and range of promises. Stem Cell Rev Rep. 2021;17(1):163–75.PubMedCrossRef
7.
8.
Hui KP, et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 2020;8(7):687–95.PubMedPubMedCentralCrossRef
9.
Van der Vaart J, Clevers H. Airway organoids as models of human disease. J Intern Med. 2021;289(5):604–13.PubMedCrossRef
10.
Suzuki T et al., Generation of human bronchial organoids for SARS-CoV-2 research. bioRxiv 2020. Google Scholar, 2020.
11.
Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80.PubMedPubMedCentralCrossRef
12.
Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal–oral transmission. Gastroenterology. 2020;158(6):1518–9.PubMedCrossRef
13.
Chen L, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.PubMedCrossRef
14.
Chiu C, Moss CF. The role of the external ear in vertical sound localization in the free flying bat, Eptesicus fuscus. J Acoust Soc Am. 2007;121(4):2227–35.PubMedCrossRef
15.
Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43(7):648–54.PubMedPubMedCentralCrossRef
16.
Hanff TC, et al. Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations. Clin Infect Dis. 2020;71(15):870–4.PubMedPubMedCentralCrossRef
17.
Danser AJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75(6):1382–5.PubMedCrossRef
18.
Derington CG, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005–2016. Hypertension. 2020;75(4):973–81.PubMedCrossRef
19.
20.
Talreja H, et al. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019). NZ Med J. 2020;133(1512):85–7.
21.
Rahman N, et al. Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules. 2020;25(10):2271.PubMedPubMedCentralCrossRef
22.
Jackson CB, et al. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.PubMedCrossRef
23.
24.
25.
Bojkova D et al., SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles. BioRxiv, 2020.
26.
Ulrich H, Pillat MM. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep. 2020;16(3):434–40.PubMedPubMedCentralCrossRef
27.
28.
Wang K, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther. 2020;5(1):1–10.
29.
30.
31.
Atala A, et al. Regen med therapeutic opportunities for fighting COVID-19. Stem Cells Transl Med. 2021;10(1):5–13.PubMedCrossRef
32.
Han Y et al., Identification of candidate COVID-19 therapeutics using hPSC-derived lung organoids. BioRxiv, 2020.
33.
34.
Lamers MM, et al. An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. EMBO J. 2021;40(5): e105912.PubMedPubMedCentralCrossRef
35.
Ziegler CG, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181(5):1016–35.PubMedPubMedCentralCrossRef
36.
37.
Tiwari SK, et al. Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell-derived lung and cerebral organoids. Stem Cell Rep. 2021;16(3):437–45.CrossRef
38.
Salahudeen AA et al., Progenitor identification and SARS-CoV-2 infection in long-term human distal lung organoid cultures. BioRxiv, 2020.
39.
Mykytyn AZ, et al. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. Elife. 2021;10: e64508.PubMedPubMedCentralCrossRef
40.
Mukerji SS, Solomon IH. What can we learn from brain autopsies in COVID-19? Neurosci Lett. 2021;742: 135528.PubMedCrossRef
41.
Neumann B et al., Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms. J Neurol Sci 2020;418.
42.
Mao L, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan. China JAMA Neurol. 2020;77(6):683–90.PubMedCrossRef
43.
Montalvan V, et al. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194: 105921.PubMedPubMedCentralCrossRef
44.
45.
Zhang B-Z, et al. SARS-CoV-2 infects human neural progenitor cells and brain organoids. Cell Res. 2020;30(10):928–31.PubMedCrossRef
46.
Jacob F, et al. Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. Cell Stem Cell. 2020;27(6):937–50.PubMedPubMedCentralCrossRef
47.
Pellegrini L, et al. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell. 2020;27(6):951–61.PubMedPubMedCentralCrossRef
48.
49.
Giannoni P, et al. The pericyte–glia interface at the blood–brain barrier. Clin Sci. 2018;132(3):361–74.CrossRef
50.
51.
Jin Z, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–93.PubMedCrossRef
52.
Holshue ML et al., First case of 2019 novel coronavirus in the United States. New England J Med 2020.
53.
54.
Zhou J, et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat Med. 2020;26(7):1077–83.PubMedCrossRef
55.
Wei X-S, et al. Diarrhea is associated with prolonged symptoms and viral carriage in corona virus disease 2019. Clin Gastroenterol Hepatol. 2020;18(8):1753–9.PubMedPubMedCentralCrossRef
56.
Xu Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502–5.PubMedPubMedCentralCrossRef
57.
Han Y, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2021;589(7841):270–5.PubMedCrossRef
58.
Giobbe GG, et al. SARS-CoV-2 infection and replication in human gastric organoids. Nat Commun. 2021;12(1):1–14.CrossRef
59.
Duan X et al., Identification of drugs blocking SARS-CoV-2 infection using human pluripotent stem cell-derived colonic organoids. 2020.
60.
Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the Treatment of Covid-19-Preliminary Report Reply. The New England J Med. 2020;383(10):994–994.
61.
Kupferschmidt K, Cohen J, WHO launches global megatrial of the four most promising coronavirus treatments. Science 2020;22(03)
62.
Krüger J, et al. Drug inhibition of SARS-CoV-2 replication in human pluripotent stem cell–derived intestinal organoids. Cell Mol Gastroenterol Hepatol. 2021;11(4):935–48.PubMedCrossRef
63.
Freedberg DE, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020;159(3):1129–31.PubMedCrossRef
64.
Xiao F, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–3.PubMedCrossRef
65.
Lamers MM, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50–4.PubMedCrossRef
66.
67.
Little P. Non-steroidal anti-inflammatory drugs and covid-19. British Medical Journal Publishing Group; 2020.CrossRef
68.
Ong J, Young BE, Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69(6):1144–5.PubMedCrossRef
69.
70.
Liu J, Li S, Liu J, Longitudinal characteristics of lymphocyte responses and cytokine pro les in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine [Internet]. 2020 Apr 18 PMC7195532]; 55:[102763 p.].
71.
Chai X et al., Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv, 2020.
72.
73.
Zhu L, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068–77.PubMedPubMedCentralCrossRef
74.
75.
Qiu H, et al. Acute on chronic liver failure from novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Liver Int. 2020;40(7):1590–3.PubMedCrossRef
76.
Wichmann D, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268–77.PubMedCrossRef
77.
78.
Braun F, et al. SARS-CoV-2 renal tropism associates with acute kidney injury. The Lancet. 2020;396(10251):597–8.CrossRef
79.
80.
Bouquegneau A et al., COVID-19-associated nephropathy includes tubular necrosis and capillary congestion, with evidence of SARS-CoV-2 in the nephron. Kidney360, 2021.
81.
Müller JA, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149–65.PubMedCrossRef
82.
Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The lancet. 2020;395(10223):497–506.CrossRef
83.
Li Z et al., Caution on kidney dysfunctions of COVID-19 patients. 2020.
84.
85.
86.
87.
88.
89.
Xia S, et al. Long term culture of human kidney proximal tubule epithelial cells maintains lineage functions and serves as an ex vivo model for coronavirus associated kidney injury. Virologica Sinica. 2020;35(3):311–20.PubMedPubMedCentralCrossRef
90.
Allison SJ. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2. Nat Rev Nephrol. 2020;16(6):316–316.PubMedPubMedCentral
91.
Monteil V, et al. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med. 2021;13(1): e13426.PubMedCrossRef
92.
Napoli PE et al., The ocular surface and the coronavirus disease 2019: does a dual ‘ocular route’exist? 2020, Multidisciplinary Digital Publishing Institute. p. 1269.
93.
94.
Makovoz B, Moeller R, Eriksen AZ, SARS-CoV-2 infection of ocular cells from human adult donor eyes and hESC-derived eye organoids. Social Science Research Network, 2020.
95.
Casagrande M, et al. Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients. Ocul Immunol Inflamm. 2020;28(5):721–5.PubMedCrossRef
96.
Burgos‐Blasco, B., et al., Optic nerve analysis in COVID‐19 patients. Journal of Medical Virology, 2021.
97.
98.
99.
Pereira LA, et al. Retinal findings in hospitalised patients with severe COVID-19. Br J Ophthalmol. 2022;106(1):102–5.PubMedCrossRef
100.
101.
102.
Ahmad Mulyadi Lai HI, et al. Expression of endogenous angiotensin-converting enzyme 2 in human induced pluripotent stem cell-derived retinal organoids. Int J Mol Sci. 2021;22(3):1320.PubMedPubMedCentralCrossRef
103.
Menuchin-Lasowski Y et al., SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids. Stem Cell Reports, 2022.
104.
105.
106.
107.
108.
109.
Ou J, et al. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity. J Virol. 2021;95: e0061721.PubMedCrossRef
110.
111.
Tegally H, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–43.PubMedCrossRef
112.
Edara VV, et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. New England J Med. 2021;385:664–6.CrossRef
113.
Implications of the Emergence and Spread of the SARSCoV-2 B.1.1.529 Variant of Concern (Omicron), for the EU/EEA; ECDC: Stockholm, Sweden, European Centre for Disease Prevention and Control. 2021.
114.
115.
116.
117.
Ferguson N et al., Population Distribution and Immune Escape of the Omicron in England; Imperial College London: London, UK, 2021.
118.
Pulliam JRC, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376:6593.CrossRef
119.
Planas D, et al. Reduced Sensitivity of SARS-CoV-2 Variant Delta to Antibody Neutralization. Nature. 2021;596(7871):276–80.PubMedCrossRef
120.
Wang P, et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–5.PubMedCrossRef
121.
122.
Wu K et al., mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv, 2021. 01.25.427948.
123.
Madhi SA, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. The New England J Med. 2021;384:1885–98.CrossRef
124.
Novavax Confirms High Levels of Efficacy against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials. 2021.
125.
Huang B et al., Neutralization of SARSCoV-2 VOC 501Y.V2 by human antisera elicited by both 1 inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines 2 3 Authors. bioRxiv. Cold Spring Harbor Laboratory, 2021.02.01.429069.
126.
Le GR, et al. COVA1–18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Res Square. 2021;2(1):6097.
127.
De Gasparo R et al. Bispecifc antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease 2 3. bioRxiv,2021. 01.22.427567.
128.
Metadata
Title
Insights into organoid-based modeling of COVID-19 pathology
Authors
Mohadese Hashem Boroojerdi
Tariq Al Jabry
Seyed Mohamad Javad Mirarefin
Halima Albalushi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-01996-2

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue

Research

Ultrastructural study confirms the formation of single and heterotypic syncytial cells in bronchoalveolar fluids of COVID-19 patients

Brief Report

Influenza vaccine effectiveness in patients hospitalized with severe acute respiratory infection in Lithuania during the 2019–2020 influenza season: a test negative case – control study

Research

Exaggerated levels of some specific TLRs, cytokines and chemokines in Japanese encephalitis infected BV2 and neuro 2A cell lines associated with worst outcome

Research

Anti-human immunodeficiency virus-1 activity of MoMo30 protein isolated from the traditional African medicinal plant Momordica balsamina

Research

Peptide aptamer-based time-resolved fluoroimmunoassay for CHIKV diagnosis

Review

Neutrophils in COVID-19: recent insights and advances

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits